FSSAI files three cases against Nestle India over infant formula violations

⚡ Key Financial Takeaways

FSSAI filed three separate adjudication cases against Nestle India for products: Infant Nutrition, NAN Excella, and Lactogen.

Lab analysis found a follow-up formula sample had sub-standard Biotin levels, confirmed by a second referral laboratory.

Promotional claims for '5 HMOs' and 'Whey Protein' on e-commerce platforms were found to violate FSS Regulations and the IMS Act, 1992.

Nestle India shares fell 2.3% to Rs 1,336 on September 18 following the regulatory announcement.

💡 Why It Matters

This case highlights the strict enforcement of infant food safety standards in India. For consumers, it underscores the regulatory scrutiny on both product quality (nutritional content) and marketing practices (prohibited claims). For the FMCG sector, it serves as a reminder that compliance with the FSS Act and IMS Act is critical to maintaining market trust and avoiding financial penalties.

Regulatory Action Against Infant Formula Products

The Food Safety and Standards Authority of India (FSSAI) has initiated legal proceedings against Nestle India Limited, citing multiple non-compliances with the Food Safety and Standards (FSS) Act. The regulator filed three distinct adjudication cases concerning the company's infant nutrition products, specifically targeting NAN Excella and Lactogen.

According to an official statement, FSSAI examined the products and their promotional materials available on e-commerce platforms. The investigation revealed that specific marketing claims violated regulations designed to protect infant food consumers.

Violations in Promotional Claims

FSSAI identified that in NAN Excella Pro Stage 1, the product listed claims regarding "5 HMOs" and "Whey Protein." Similarly, Lactogen Pro 1 included a claim stating that "Whey Protein" is easy to digest.

The authority noted that these claims contravene Regulation 4(2) of the FSS (Foods for Infant Nutrition) Regulations, 2020. This regulation restricts promotional materials intended to increase the saleability of infant foods. Additionally, the actions violate Section 3 of the Infant Milk Substitutes, Infant Food, and Child Complementary Food Act (IMS Act), 1992, which prohibits the advertisement and promotion of such products.

Sub-Standard Biotin Levels Detected

Beyond marketing violations, laboratory analysis revealed quality control issues. A sample of a follow-up formula manufactured by Nestle India was found to be sub-standard regarding its Biotin content. The initial lab test indicated the sample fell below the required Biotin level. When the sample was sent for re-analysis to a referral laboratory, the second test also confirmed that the product did not meet the prescribed Biotin requirements under the 2020 regulations.

Market Reaction

The regulatory action had an immediate impact on the stock market. On September 18, Nestle India shares declined by 2.3% as of 1:30 pm, trading at Rs 1,336 per share. The drop reflects investor concern over potential penalties and reputational risks associated with the FSSAI's enforcement actions.

🏛️ Background & Context

The FSS (Foods for Infant Nutrition) Regulations, 2020, and the IMS Act, 1992, are designed to ensure that infant foods are safe, nutritious, and not subject to misleading or aggressive marketing. Biotin is a B-vitamin essential for metabolism, and its presence in infant formulas is strictly regulated to ensure proper infant development.

👁️ What To Watch Next

Readers should watch for the outcome of the three adjudication cases filed by FSSAI. The final penalties or corrective actions ordered by the authority will determine the financial and operational impact on Nestle India. Additionally, any changes to the company's product labeling or e-commerce listings in response to the regulatory findings will be significant developments.